$-0.19 EPS Expected for SenesTech, Inc. (SNES)

March 15, 2018 - By Peter Erickson

 $ 0.19 EPS Expected for SenesTech, Inc. (SNES)

Analysts expect SenesTech, Inc. (NASDAQ:SNES) to report $-0.19 EPS on March, 29.After having $-0.28 EPS previously, SenesTech, Inc.’s analysts see -32.14 % EPS growth. The stock increased 4.28% or $0.03 during the last trading session, reaching $0.65. About 79,796 shares traded. SenesTech, Inc. (NASDAQ:SNES) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. The company has market cap of $10.26 million. The firm focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It currently has negative earnings. It is also developing a pipeline of fertility control and animal health products, including plant fertility control, feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.

More notable recent SenesTech, Inc. (NASDAQ:SNES) news were published by: Bizjournals.com which released: “Meet Arizona’s newest public company” on December 09, 2016, also Streetinsider.com with their article: “SenesTech, Inc. (SNES) Climbs 100% After Announcing Distribution Agreement …” published on October 23, 2017, Marketwatch.com published: “SenesTech Inc.” on December 08, 2016. More interesting news about SenesTech, Inc. (NASDAQ:SNES) were released by: Prnewswire.com and their article: “SenesTech Announces Management Restructuring and Changes to Board of Directors” published on January 06, 2016 as well as Streetinsider.com‘s news article titled: “SenesTech, Inc. (SNES) Prices Offering of Common Stock and Warrants” with publication date: November 17, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: